Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 17/20 | 0.62 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.62 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.62 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2720847 | 0.94 | MAP2K1 (0.63) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 | |
| SCHEMBL18518860 | 0.91 | MAP2K1 (0.52) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 | |
| SCHEMBL12275536 | 0.90 | MAP2K1 (0.51) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 | |
| SCHEMBL2717523 | 0.86 | MAP2K1 (0.64) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 | |
| SCHEMBL18518767 | 0.85 | MAP2K1 (0.53) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 | |
| SCHEMBL2720047 | 0.85 | MAP2K1 (0.64) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL5559179 | 0.84 | MAP2K1 (0.44) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL2718739 | 0.84 | MAP2K1 (0.49) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL5555065 | 0.83 | MAP2K1 (0.67) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL2720164 | 0.83 | MAP2K1 (0.63) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635587-B1 | 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO LTD (CN) | 2017-02-15 | — | — | EP | disclosed |
| EP-2635587-B1 | 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO LTD (CN) | 2017-02-15 | — | — | EP | disclosed |
| US-9540396-B2 | 6-arylamino pyridone carboxamide as MEK inhibitors | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-01-10 | — | — | US | disclosed |
| US-9540396-B2 | 6-arylamino pyridone carboxamide as MEK inhibitors | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-01-10 | — | — | US | disclosed |
| US-20140080804-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-03-20 | — | — | US | disclosed |
| US-20140080804-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-03-20 | — | — | US | disclosed |
| EP-2635587-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | Centaurus Biopharma Co., Ltd. (CN) | 2013-09-11 | — | — | EP | disclosed |
| US-20120238599-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-09-20 | — | — | US | disclosed |
| US-20120238599-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-09-20 | — | — | US | disclosed |
| US-20120238599-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-09-20 | — | — | US | disclosed |
| WO-2012059041-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012059041-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080804-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | MAP3K6, MAP3K1, MAP3K21 | MAP2K1 44/4885MAP2K2 45/4885MAP2K5 35/4885 |
| US-20120238599-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | BRAF, MAP3K1, MAP3K11 | MAP2K1 41/4885MAP2K2 39/4885MAP2K5 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.